Kratom debate: bereaved families urge ban; patients and clinicians press for regulation

The committee heard sharply contrasting testimony on two competing bills: H4261 (a proposal to schedule kratom alkaloids as Class A controlled substances) and H2454 (a kratom consumer-protection and regulation approach). Bereaved parents described sudden deaths they attributed to kratom products and urged an outright ban. Dan Gibbs testified that his 25-year-old son "died alone in his bedroom" from mitragynine toxicity with no other substances present and called for scheduling the alkaloids as Class A substances.

By contrast, chronic-pain patients, clinicians and some recovery advocates described whole-leaf kratom as a life-changing, harm-reduction alternative to opioids. Many urged a targeted ban of novel synthetic derivatives (often referenced as "7‑OH" or variants) and a regulatory approach including mandatory lab testing, accurate labeling and age limits. Clinicians warned that an outright ban would remove a tool that some patients use to reduce opioid use and regain functioning.

Committee members heard requests for data on toxicology trends, the role of synthetic derivatives versus traditional leaf preparations, enforcement implications and the likely public-health outcomes of either policy path. No vote was taken; committee asked for additional written evidence, forensic toxicology data and comparative regulatory models.